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Dugan: The Legal and Social Implications of Psychopharmacology

THE LEGAL AND SOCIAL IMPLICATIONS OF
PSYCHOPHARMACOLOGY
One out of every four-adults in the United States has taken
a psychotropic' agent in the last year; one out of every two has
taken a psychotrope at some time in his life.2 Since their introduction in the 1950s, the new psychotherapeutic drugs have attained a position of importance in the armamentarium of the
physician. Whether the increase in the use of these drugs is the
result of "turbulent times," of promotional efforts, or "of sloppy
prescribing practices of clinicians is uncertain." I There is, however, reason to believe that psychopharmacology will hold a
unique position within drug liability in much the same way that
the latter has been sui generis within products liability. 5
I.

NATURE AND USE OF PSYCHOTROPIc DRUGS

A.

What is a Psychotrope?

"Psychotropic agents are defined as those substances which
have their main or principal effect on mood, thought processes,
or behavior."' There are six classes of psychotropic agents: major
tranquilizers, minor tranquilizers, antidepressant agents, stimulants, sedatives, and hypnotics. Over the counter (OTC) psychotropes have been set aside for the bulk of this article.8 It is impor1. The terms "psychotropic", "psychotherapeutic" and "psychopharmacological"
are used interchangeably throughout this article. For a definition, see text accompanying
note 6, infra.

2. Baiter and Levine, The Nature and Extent of Psychotropic Drug Usage in the
United States, 5 PSYCHO-PHARMACOLOGY BULL. 3, 7 (1964-69).
3. Parry, et al., National Patterns of PsychotherapeuticDrug Use, 28 ARCH. GEN.
PSYCHIATRY 769, 770 (1973).
4. Hollister, Clinical Use of PsychotherapeuticDrugs Ik Antidepressant and Antianxiety Drugs andSpecialProblems in the Use of PsychotherapeuticDrugs,4 DRUGS 361,
:386 (1972).
5. RESTATEMENT

(SECOND) OF TORTS §402A, Comment k, at 353-54 (1965):
There are some products which, in the present state of human knowledge, are
quite incapable of being made safe for their intended and ordinary use. These
are especially common in the field of drugs. . . . Such a product, properly
prepared, and accompanied by proper directions and warning, is not defective,
nor is it unreasonably dangerous.
See also, Rheingold, ProductsLiability-The EthicalDrug Manufacturer'sLiability, 18
RUTc,ERS L. REV. 947 (1964).
6. Balter and Levine, supra note 2, at 4.
7. See Appendix I. The chart was taken from Parry, et al., supra note 3, at 772.
8. Over the counter psychotropes include stimulants (e.g., No-doz), tranquilizers
(e.g., Cope and Compoz) and sleeping pills (e.g.& Sominex and Sleep-Eze). See Appendix

I.
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tant to note that these "[p]sychotherapeutic agents act by unknown mechanisms to reduce the level of symptomatology of patients but do not . . . directly affect the causative agent of the
illness in the same manner as antibiotic agents attack the microbes which cause infectious diseases." 9 This is because the
etiology of psychiatric disorders is essentially unknown."0 Therefore, most psychiatric disorders are hypothetical entities postulated from psychological and physical symptoms manifested by
an individual.
The major tranquilizers were introduced into widespread use
in the mid-1950s. 11 The phenothiazine-related compounds
compose the bulk of this class of drugs. They are primarily
thought of as agents effective in the treatment of one of the major
psychiatric disorders, psychosis, and thus, are often termed antipsychotic drugs. The most common side effects of these compounds include drowsiness and extrapyramidal symptoms such
as are seen in Parkinson's disease; drug dependence of a
psychological or physiological nature does not occur. 2 The minor
tranquilizers appeared about the same time as the major tranquilizers and are considered to be antianxiety agents. They may
produce a physiological dependence similar to that known to
occur with barbiturate drugs. 3
The antidepressant drugs came some years after the major
and minor tranquilizers.'4 There are two principal categories: the
tricyclic series and the monoamine oxidase (MAO) inhibitors.
There is some evidence that concurrent consumption of a tricyclic
and a MAO inhibitor results in a toxic state; physiological dependence, however, has not been established in this class of
drugs.
The stimulant class, of which amphetamines constitute the
bulk, are used to treat obesity and to some extent depression,
since they have marked effects on the central nervous system."
These drugs are subject to considerable illicit use and when taken
in sufficient quantities lead to psychotic paranoia.
9. Baiter and Levine, supra note 2, at 3.
10. Id.
11. Id., at 4.
12. Id.
13. Id., at 5.
14. Id.
15. See Beaumont, Drug Interactionswith Clomipramine(Anafranil), 1 J. INT. MED.
REs. 480 (1973).
16. Baiter and Levine, supra note 2, at 5.
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The sedatives, which are mostly barbiturates, have been
available for a long period of time. Both psychological and physiological dependence exist with this class.' 7 The hypnotic class
of drugs is effective in the treatment of sleep disturbances. When
taken in large doses, marked intoxication results, and, over a
period of time, severe psychological and physiological
dependence can occur.'
B. Societal Attitudes
Psychiatry is the only medical specialty in which generalizations about methods of treatment substitute for actual clinical
experience. It is also the only specialty about which laymen
have strong opinions for or against procedures in which they
have either infinite faith or which they totally condemn."
There exist at least three views toward the use and development of psychotropic drugs. It seems that often these views are

less predicated on profound convictions than on the popular view
of such drugs: 20
Earlier popularized accounts of psychotherapeutic drugs as
'miracle drugs' appearing in the mass media-not infrequently

in the same publications which have swung around to viewing
the same drugs with alarm-have played their part in generat-

ing awareness of such drugs.
Nevertheless, there are those who perceive that decisions made
in this field require assiduous scrutiny of a whole gamut of values-scientific, social, legal and ethical.
One view of these drugs is rooted in our history and has been
termed "pharmacological Calvinism.

21

This is a puritanical ap-

proach whose purpose is "abstinence from all chemical substances.

22

Adherents view current phenomena in the drug field

as being exemplary of general moral decadence. Struggle and
pain are concomitants of human existence and thus, drug con17. Id.

18. Id.
19. Hearingson Drug Safety Before the Subcomm. on IntergovernmentalRelations
of the House Comm. on Government Operations,88th Cong., 2d Sess., pt. 3, at 1221 (1964)
Ihereinafter cited as Drug Safety Hearings], (quoting from an article by Lothar B.
Kalinowskiy, M.D., printed in the American Journal of Psychiatry, April 1964.)
20. Parry et al., supra note 3, at 770.
21. Klerman, Drugs and Social Values, 5 Int. J. Addictions 313, at 316 (1970).
22. Klerman, The Therapeutic Future of Mind-Altering Drugs, 63 J. School Health
116, 120 (February 1973).
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sumption resulting from an inability to cope with stress is considered a weakness of the highest order. Tension, anxiety, depression
and despair "are all part of the normal repertoire of everyday
life." 2 By themselves, these moods and emotions are not considered pathological. 4
They are part of an individual's capacity to experience emotion
as a part of his biological heritage, and they play an important
adaptive
role in facilitating man's adjustment to his environ25
ment.
This philosophy imparts the simple notion that "[i]f a drug
2' 6
makes you feel good, it must, somehow, be bad.
The antithesis of this position "combines permissiveness
with the expectation that life could, and indeed should, be
free from care and stress."" Psychotherapeutic drugs become
"simply adjuncts of comfort and utility. 28 It is maintained that
the dilemma with respect to mind-altering drugs is merely history
repeating itself. When coffee and tobacco were introduced, they
were the subject of as much debate as now surrounds marijuana.28
As is the situation with most polarities, the truth lies somewhere in the middle. It is unfortunate, however, that doctors
often find themselves in the position of adjudicating these philosophical and emotional conflicts. In fact, psychiatrists themselves eschew being characterized as drug therapists."5 The author
believes that the most productive orientation is a moderate one,
whereby we prescind from the enticing opportunity to indulge in
moral indignation and instead examine the facts:3"
23. Id., at 119.
24. The opinions regarding drug intake for these "moods" should and probably do
become less stringent as one begins to discuss the more serious "mental disorders" such
as manic depression or schizophrenia.
25. Klerman, supra note 22, at 119.
26. Id., at 120.
27. Parry et al., supra note 3, at 770.
28. Id.
29. Klerman, supra note 22, at 120.
30. A survey of 360 psychiatrists' attitudes toward treatment disclosed a major professional inconsistency. Eighty percent of the psychiatrists rated themselves as being
psychotherapists ("talk" therapy) even though most of them were not doing any
psychotherapy. Only ten percent considered themselves somatic (drug) therapists even
though the majority in public mental hospitals were prescribing large amounts of psychoactive drugs. See Pearlin and Klerman, CareerPreferences of PsychiatricResidents,
29 PSYCHIATRY 56 (1966); Armor and Klerman, Psychiatric Treatment Orientationsand
ProfessionalIdeology, 9 J. HEALTH AND SOCIAL BEHAVIOR 243 (1968).
31. Parry, et al., supra note 3, at 771.
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[T]here is such a thing as mental illness, and the major tranquilizers and anti-depressants perform a valuable role in its
treatment. There are minor neurotic states and for these the
various less-powerful psychotherapeutic drugs perform a useful
temporary function ....
Upon recognizing a legitimate need for psychotropic drugs, the
problem which arises is how to ensure as much as possible that
these drugs are effective and not unreasonably dangerous, and
that the right drugs get to the right persons in the right amounts.
This problem necessitates the kind of analysis commonly used in
the products liability field: risk versus benefit. It also entails
considerations beyond the legal sphere. As one doctor depicted
32
the analysis:
There is no question but that drugs are one of the major tools
our country's physicians have, both for preventing and treating
disease, and as such, they constitute one of our most important
resources for an effective health care system. At the same time,
misuse and overuse of drugs, and wastage of drugs - in the
sense that some products do not benefit the patient and have
no rational use in therapy-pose some of the most important
medical and social questions of the day.
C.

Use and Overuse of Psychotropic Drugs

The resounding question is whether psychotropic drugs are
being overprescribed and overused in the United States. "Unfortunately, this issue is more easily raised than answered if conclusions are to be documented and factual rather, than opinionated
and judgemental. ' 3 3 Statistical studies have been conducted in
an attempt to ascertain usage trends for psychotropic drugs in the
United States.3 4 It has been determined that "[i]n the year 1970,
the last reported, some 214 million prescriptions were filled in
American drugstores for . . .the main classes of psychotherapeutic drugs. These drugs in 1970 accounted for 17 percent of the
total prescriptions of all kinds filled in drugstores in the United
States (including refills) .,,3Data collected for the year 1967 show
that "there were 54.1 new prescriptions for psychotropic drugs
filled for every 100 of adult population."3 6 The figures reflected an
32.
33.
34.
35.
36.
equally

Edwards, Rational Drug Therapeutics, FDA Papers, Feb., 1971, at 4.
Id.
See, e.g., id.; Parry et al., supra note 3.
Parry et al., supra note 3, at 770.
Balter and Levine, supra note 2, at 6. Of course, these drug acquisitions are not
distributed per person.
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increase of 65 percent in the number of new psychotropic drug
prescriptions between 1958 and 1967, as opposed to a 35 percent
increase for all other drugs in the same period. 31 "When trends for
new psychotropic drug prescriptions are broken down by major
drug class, it becomes apparent that the large overall increase
* . . is mainly attributable to minor tranquilizers . . . ."I Currently, chlordiazepoxide (Librium) and diazepam (Valium) are
the most popular, accounting for almost 50 percent of retail sales
of tranquilizers in the first half of 1970.:1 "Here, we are on the
borderline between medical practice and social values. We are in
debatable area because one, we are dealing with value questions,
and two, we do not have good data."4 0
An interesting aspect of the "minor tranquilizer phenomena"
is that, although ". . . it can be seen that current prevalence
rates for prescription psychotherapeutic drugs are twice as high
for women as for men, ' ' 4' most of the statistical difference between sexes can be accounted for by a single broad class of drugs
- the minor tranquilizer/sedative group." . ' Perhaps one explanation of the high consumption level among women is that male
drug prevalence rates with respect to "substitute" substances,
specifically alcohol and marijuana, are substantially higher than
female rates.42 Contrary to the image of the "pill-popping" middle class housewife, the data show that the lowest socioeconomic
4
stratum is responsible for most of the high drug use3.
Drawing
inferences from "high" drug use may be misleading in that a
smaller percentage of low income users with a serious "high" level
of consumption can outweigh a more pervasive, albeit more indi37. Id., but note that part of the increase in new psychotropic drug prescrptions for
1966 is due to the passage of the Drug Abuse Control Amendments of 1965, 21 U.S.C.
§ 374 (1970), which set limits on the number of refills for sedative, stimulant and hypnotic
drugs. Thus, a sharp increase in new prescriptions resulted.
38. Id.
39. Shader, Drugs in the Management of Anxiety, 11 CURR. PsYcM. THER. 81, 82
(1971).
40. Klerman, A Reaffirmation of the Efficacy of Psychoactive Drugs: A Response to
Turner, 1971 J. DRUG IssuEs 312, 315.
41. Parry et al., supra note 3, at 774.
41.1. Id., at 774-75.
42. Id., at 775.
43. Id., at 779. This may indicate that middle class women are more moderate in their
use; the fact that the lower socioeconomic levels are reproting greater prevalence rates for
"high" drug use is thought to be a result of waiting "until symptoms are more serious and
that consequently the drugs must be taken over longer periods of time."; id.; see text
accompanying note 68 infra for a discussion of manufacturer's selling tactics with respect
to housewives.
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vidually moderate trend among middle class users. The author's
personal, though limited, investigation reaffirms this: a suburban
pharmacist gave sobering statistics on minor tranquilizer sales in
an upper middle class area.44
It was found that these drugs are most often prescribed by
general practitioners and internists and usually on an "as
needed" basis.4 5 Ironically, psychiatrists are not the big
prescribers of psychotropic drugs:46
Even in the case of antidepressants and major tranquilizers,
primarily prescribed for mental disorders, psychiatrists and
neurologists account for only about a third of the prescriptions
written. Our own findings, approaching the issue from the
direction of the patient, indicate that: 85% of our respondents
who had used prescription psychotherapeutic drugs in the year
preceding our survey reported they had never seen a psychiatrist
in their lives.
The fact that ".

.

. over 70 percent of all prescriptions for psycho-

tropic agents are written by general practitioners, interns and
surgeons" 47 does not necessarily mean that they are usurping the
psychiatric domain, for "new therapy with minor tranquilizers is
just as likely to be directed to patients with a primary diagnosis
of physical disorder as it is to persons with a primary diagnosis
of mental disorder.

48

However, the data indicate that the physi-

cian's specific therapeutic intent at the time of prescribing is to
alleviate symptoms of psychic or emotional distress regardless of
the actual etiology. 9 The fact that general practitioners are treating essentially psychic disorders causes difficulty with respect to
those patients who do ultimately see a psychiatrist and one can
only conjecture about the situation of those who fail to do so. One
psychiatrist depicted the danger thusly: "[I]n our practical work
we specialists hardly ever see depressed patients who did not
44. Interview with Louis Biundo, Greenvale Pharmacy, Greenvale, N.Y. He stated
that monthly sales of Valium were 6,000, 3,000 and 1,500 for the 5 mg., 2 mg., and 10 mg.
pills respectively or a total of 51,000 mg. per month. Librium sales average about half as
much as those of Valium. Interestingly, he said that although the pharmacy's business
could be roughly broken down to 75% Roslyn (upper middle class to wealthy), and 25%
Greenvale (lower middle class), 97% of minor tranquilizer sales were attributable to the
Roslyn clientele.
45. Baiter and Levine, supra note 2, at 12.
46. Parry et al., supra note 3, at 770.
47. Baiter and Levine, supra note 2, at 10.
48. Parry et al., supra note 3, at 774.
49. Id.
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already have some trial with antidepressant medication. The general practitioner is the first to prescribe these drugs, often in
inadequate amounts."5 Dr. Nathan Kline, who heads the largest
private practice in the country which specializes in psychopharmacology, has encountered similar problems. 51 He indicated that
letters have arrived frequently from persons who have been receiving medication for various mental or emotional disorders
from general practitioners. 52 Often the medication is prescribed
in inappropriate dosages for the patient's condition and at times
the drug's action could serve only to enhance the symptoms.
D. Is there a "Cure" for Overuse?
Since general practitioners are "consistently overrepresented on use of all classes of psychotropic agents,"" and
since the drugs are often the subject of conflicting opinion even
among the specialists in the field,54 it would seem logical to give
serious consideration to restricting prescribing by general practitioners at least until the nature of psychotropic drugs is better
and more widely understood. For example, while FDA approval
of Parnate (MAO inhibitor) was engendering controversy, the
manufacturer ". . . itself [had] suggested the possibility of restricting use of the drug to hospitalized patitents who were under
the care of psychiatrists." 51 Prescinding from the difficulty of
differentiating psychiatric from non-psychiatric use of psychotropes, a major outcry in response to a restriction of psychotropic
prescriptions would be forthcoming from the medical profession,
which has been traditionally allowed to prescribe any drugs approved by the FDA and some that are being investigated. 5 The
American Medical Association has often reflected doctors' "fears
of losing their independence to government control . . . . "'7 The
physician's classical role in drug liability cases" as an automatic
50. Drug Safety Hearings, supra note 19, pt. 3, at 1222 (quoting article).
51. Doctor Kline's office is located at 40 East 69th Street, New York City. He is also
Director of Research at Rockland State Hospital.
52. Interview with Dr. Kline on December 12, 1973.
53. Balter and Levine, supra note 2, at 10.
54. See section II, infra.
55. Drug Safety Hearings, supra note 19, pt. 3, at 1216.
56. 21 U.S.C. §355(i) (1970).
57. New York Times, Dec. 9, 1973, §4, at 6, col. 1.
58. "No court has yet held that a physician's departure from any protion of the
approved labeling [or directions] conclusively establishes negligence," Merrill,
Compensationfor PrescriptionDrug Injuries, 59 VA. L. REv. 1, 53 (1973). In most jurisdictions a physician who follows the community standard of good medical practice is not
negligent. E.g., Mallet v. Pirkey, 171 Colo. 271, 466 P.2d 466 (1970).
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"independent decision maker" is perhaps not consonant with the
increase of specialization that modem technology has caused.
The fact that doctors are inundated with information of varying
degrees of importance and pertaining to fields with respect to
which they may or may not be expert is virtually common knowledge. 9 "If so, does this not raise a question concerning the extent
to which FDA can rely on the discretion of individual medical
practitioners, in balancing the advantages and hazards of a
drug?"6 The broader question is one involving the scope of intervention on the part of the federal government. Should the individual proficiencies of physicians be subject only to license and
regulation by the states? And, if so, does the responsibility of the
FDA terminate once an approved drug is placed before persons
who are licensed by the states to practice medicine? While licensing may be properly the province of the states, regulation of available drugs is a continual process. If the FDA concludes that misuse of a drug is widespread and that it should not regulate the
practice of medicine, it has no choice but "to say this drug is in
fact doing more harm than good, so we will take it off the market."'" In products liability it is the de facto use of a product
of its danger, not the
which determines the unreasonableness
2
intended or proper use thereof.
The second outcry in response to an attempt to curb excessive prescribing practices among general practitioners would be
from the manufacturers. The crucial question is: if, in fact, a drug
is being overused, or if it is causing serious side effects, will any
company in America be willing to lose a 5 to 10 million dollar
market to correct it? 3 Manufacturers, confronted as they are with
the intersection of ethical and economic considerations, choose to
59. E.g., Yarrow v. Sterling Drug, Inc., 263 F. Supp. 159, 163 (D.S.D. 1967).
One example of the varied and often conflicting information received by doctors is
the package inserts for Stelazine and Prolixin (major tranquilizers): "[tihe Stelazine
package insert states 'In most cases (psuedo-Parkinsonism) symptoms are readily reversible when an anti-Parkinsonism agent is administered concomitantly.' The package insert
for Prolixin . . .states 'A persistent psuedo-Parkinsonism syndroyndromme Isicl may
develop . . .(for which) anti-Parkinsoian agents are seldom of benefit.' What is a physician to do? . . .IHie is under or misinformed." Turner, A CriticalAssessment of Drug
Marketing Practices, 1971 J. DRu. ISSUFs 301, 304.
60. Drug Safety Hearings, supra note 19, pt. 1, at 180.
61. Id.
62. In Incollingo v. Ewing, 444 Pa. 263, 282 A.2d 206 (1971), the court found that
despite adequate warnings on the drug label, the manufacturer could be liable for a de
facto overuse among the medical profession where the manufacturer took no steps to
minimize, and in fact encouraged, such use.
63. Turner, supra note 59, at 306.
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enhance consumption through advertising, 4 employment of
detail men,65 and other promotional avenues. "A series of congressional investigations . . . already revealed the industry to be a
high-profit group often not as vitally concerned with health as the
investigators might have expected it to be. . .. "I The industry
has been accused of lacking any ethical compulsions and of simply "pushing" the product as it is done in any other industry. For
example, the detail manual for the introduction of Stelazine 7
places emphasis on the ". . . . calming effect. . . and. . . the
busy housewife whom most doctors agree is a 'natural' patient
type."" The objective of the promotional campaign is "to remind
the M.D. that 'Stelazine' can calm without sedating-a feature
of special value [to] housewives and other active patients.""0
Subsequent to the introduction of Stelazine, the FDA requested
the company to delete from the package insert the assertion that
the drug does not cause drowsiness.'" The detail manual even
gave exemplary conversations and starter packets contained with
the directive: "[t]ry them on your next three housewives
...
"' Interestingly, Stelazine is a phenothiazine derivative
(major tranquilizer) and therefore an antipsychotic drug. "One
should bear in mind that to take antipsychotic drugs, one must
be crazy, either literally or figuratively. 7 2 Instructions were also
64. Manufacturers spend $3,000 per year per physician. Merrill, supra note 58 at 25,
citing DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE, TASK FORCE REPORT ON PRESCIuPTION DRUGS, THE DRUG MAKERS AND THE DRUG DISTRIBUTORS 28 (1968), and SENATE COMM.
ON THE JUDICIARY, ADMINISTERED PRICES IN THE DRUG INDUSTRY,

S. Rep. No. 448, 87th

Cong.,

1st Sess. at 157 (1961).
65. See Comment, The Ubiquitous Detailman: An Inquiry Into His Functions and
Activities and the Louis Relating to Them, 1 HOFSTRA L. REV. 183 (1973) for an excellent
analysis of the detailman's dual role.
66. Rheingold, The MER/29 Story-An Instance of Successful Mass Diaster
Litigation, 56 CALIF. L. REV. 116, 144 (1968), citing Humphrey Committee Report, S. Rep.
No. 1153, 89th Cong., 2d Sess. (1966); Kefauver Committee Report, S. Rep. No. 448, 87th
Cong., 1st Sess. (1961); HearingsBefore the House Subcomm. on Government Operations,
88th Cong., 2d Sess. (1964-66).
67. Stelazine is a major tranquilizer of the phenothiazine group produced by Smith,
Kline and French of Phila., Pa.
68. Turner, supra note 59, at 307, quoting from the Stelazine detail manual used by
Smith, Kline and French.
69. Id.
70. Id. Turner cites a letter from Arthur Ruskin, M.D., Medical Officer, Division of
New Drugs, Bureau of Medicine to Smith, Kline and French Laboratories, Attn. Mr. T.
B. Wallace August 17, 1962. "[lt should be pointed out that tranquilization [from
Stelazinel may be accompanied by drowsiness .
71. Id.
72. Hollister, Optimum Use of Antips.ychotic Drugs, 12 CURR. PSYCH. THER. 81, 85
(1972).
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given on how to handle specific questions so as to avoid answering
them. As one commentator said, "[tlhe idea is to put the doctor
off, not to inform him . . . .This is particularly true when the
doctor asking is a generalpractitionerand not a trained psychiatrist" 13 [emphasis added]. Overall, due to the subjective nature
of the drugs' effects 74 it is easier to "play up" the efficacy of
psychotropic drugs by words like "calming," or "feels good," than
it is with drugs that have a more physiological action. "The use
of sweeping superlatives. . should be avoided.
. ,"I and the
FDA has the power to monitor misleading advertisements."
To avoid the necessity of the FDA's removing drugs because
of unbridled and perhaps indiscriminate use, and to avoid the
exploitation by manufacturers of doctors whose knowledge has
not kept pace with the swift developments in psychopharmacology, "serious efforts must be made in undergraduate and postgraduate training to insure the rational use of psychotropic
agents."7 7 This alternative is clearly preferable to any further
encroachment by government on the medical profession. It is
perhaps glib to state that the majority of physicians need to be
more informed about psychopharmaceuticals: if, however,
change does not come voluntarily, other factors will force the
improvement. "Unless physicians learn to use these drugs with
restraint, political pressures stemming from the growing problem
of drug abuse may lead to unwise constraints."7 8 And ultimately,
"[i]f regulation by the FDA, Congress, the medical profession,
and the industry itself does not result in improvement, then the
private enterprise system of civil litigation will provide the solution."79
E.

The PaternalismIssue

In a democratic society, one aspect of consideration in determining whether overuse of psychotropic drugs should be curbed,
or whether, if in fact, there is "overuse" at all is consumer desire
itself. At least some portion of both the manufacturer's and the
physician's belief that over-consumption of psychotropic drugs
73. Turner, supra note 59, at 308.
74. See section II, infra.
75. Drug Safety Hearings, supra note 19, pt. 5, at 2021, quoting from a letter from
the FDA to Gerhard A. Gesell, Esq., Oct. 9, 1963.
76. 21 U.S.C. § 352(n) (1970).
77. Balter and Levine, supra note 2, at 10.
78. Hollister, supra note 4, at 397.
79. Rheingold, supra note 66, at 148.
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does not abound is attributable to self-interest. But, what of the
individual who, not being a "pharmacological calvinist," ' says he
likes the drugs and wants them? "Three out of every four users
felt the prescription psychotherapeutic drugs helped them 'a
great deal' or 'quite a bit' ... ."8 In what other field of medicine

do we even ask the question? Is it that this class of drugs requires
a decision making process that is more broad than the traditional
one confined to the expertise of a physician? In some instances,
the physician would not prescribe such drugs at all if it were not
for the pressures of patients.82 Yet, the ".

.

. dilemma is com-

pounded by the patient's conviction that his request, tacit or
drugs is legitimate and based on
express, for psychotherapeutic
'real' needs." 3 Albeit difficult to document, the author doubts
whether the situation occurs frequently in which the patient insists he has an infection and then proceeds to specify what he
would like for it.
The course of events in the next several decades will directly
affect concepts no less significant than our philosophy of individual freedom and government regulation. As George Larrick, former Commissioner of Food and Drugs, stated:
The judgements of society are not necessarily consistent with
scientific facts. Neither are they always logical. They can be and
sometimes are arbitrary.u

He astutely added, however, that:
Even so, neither the executive nor the legislative branches of
government can long ignore them."
It is unwise to extrapolate from data indicatory that people
like the drugs. 85 Are they saying "yes" merely to a "good feeling"
or are they giving the affirmative nod, after full disclosure from
industry, government and the medical profession, to the creation
of a drug-dependent society some thirty years hence? An answer
80. See text accompanying note 21, supra.
81. Parry et al., supra note 3, at 773.

82. There is literature describing the dilemma caused by patients' requests for
psychotherapeutic drugs where the doctor is not in agreement. See Mellinger et al.,
Patternsof PychotherapeuticDrug Use Among Adults in San Francisco,25 ARCH.GEN.
PSYCHIATRY 385 (1971).
83. Parry et al., supra note 3, at 770.
84. Drug Safety Hearings, supra note 19, pt. 1, at 154.
84.1 Id.
85. See text accompanying note 81, supra.
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to the second question could hardly be implied from an affirmative response to the first! As Dr. Kline indicated,
[1lt may be that tranquilization may just be another path to
the extinction of the species. It may be that a certain amount
of disruption, disharmony, instability is part of what gives us
the thrust to keep moving, so I'm not sure that tranquility is
really what one should aim for.8"
That bulk of consumers which accounts for the excessive minor
tranquilizer sales should be giving thought to long-range considerations rather than to the short-range benefitsderived from the
drugs.
The choice is not between freedom and paternalism, for
clearly we prefer the former; there are however, degrees of freedom, and choosing on the basis of limited knowledge implies less
freedom. Jefferson felt that the appropriate aim of government
was "to restrain men from injuring one another. ' 87 Does restraining people from possibly harming themselves go "much beyond
, * * [the aim of government so as] . . . to impose unjustifiable
restrictions upon that paramount commodity - our personal
freedom? ' 8 Before advocating encroachment upon this purported freedom of indulgence, we should consider launching a
major campaign to inform the public. For example, few people
would disagree that some serious thought should precede the taking of oral contraceptives. We have already seen the imposition
of direct consumer warning requirements in oral contraception8 9
and one other area."0 For instance, the package insert for Librium
states that one animal study indicated a marked decrease in fertilization rate, offspring viability, mating interest, and maternal
nursing and care of the young associated with use of the drug. The
public should be informed of any substance that can potentially

86. Kline, Panel on Drugs and Society in the Year 2000, in PSYCHOTROPic DRUGS IN
2000 151 (W. Evans and N. Kline, eds., 1971).
87. From his great First Inaugural Address, quoted in Montgomery, Comments on
the Philosophy of Regulation Under the Federal Food, Drug, and Cosmetic Act, 28 Fool
DRUG COMrESTic L.J. 201 (1973).
88. Id.
89. 21 C.F.R. § 130.45 (1973).
90. Davis v. Wyeth Laboratories, Inc., 399 F.2d 121 (9th Cir. 1968) (with respect to
Sabin Oral polio vaccine). The Food Drug & Cosmetic Act even specifies publicity (press
releases) as an enforcement mechanism, however, the legislature has limited its use to
circumstances involving imminent danger to health or gross deception of the consumer.
21 U.S.C. § 375(b) (1970).
THE YEAR
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modify behavior that extensively. It is the author's opinion that
psychotropic theraphy is an area similar to that of the "pill" and
the Sabin vaccine in that the decision to consume goes beyond
the parameters of medical expertise.'
If we are "on the edge of a 'choose your mood' society," 92 we
should be certain that we are really "choosing" to go over that
edge. One authority mentions no less than fifteen 3 possible future
alterations of life patterns through drugs, including but not limited to areas like the regulation of sexual responses,94 control of
aggression, 5 inducement or prevention of learning, 11 and the relief or provocation of guilt97 feelings. The caveat added is that the
uncertainty is not whether drugs will be capable of doing these
things - they will - but "who should make the decisions as to
when they should be used, on whom and by whom."" At this
juncture, one would most likely conclude that more information
should be given, first, by the manufacturers to the physicians
and, second, by the industry, government and physicians to the
public. Despite the desirability of having sufficiently informed
patients and doctors, is there much that can be definitively said
regarding the new field of psychopharmacology? There is little
agreement as to what should be said and is it enough to say, "wait
until we know more?"
II.

SuBJEcTIvITY: THE INHERENT DIFFICULTY?

A.

Animal Testing

"Every compound must have a beginning. It may be born on
91. Many problems are involved with full disclosure to patients; disclosure may even
lessen the benefits of the therapy. The difficulty is acute at the testing stage where doctor
and patient bias may alter the results. See Rheingold, supra note 5, at 958. In light of this,
the 1962 Kefauver-Harris amendments allow for the doctor's discretion. Section 103(b),
76 Stat. 783 (1962), 21 U.S.C. §355(i) (1970), amending §505(i), 52 Stat. 1052 (1938).
92. Evans, Epilogue to PsYcHOTRoPIc DRUGS INTHE YEAR 2000, supra note 86, at 158,
93. See Appendix II (taken from PSYCHOTROPIc DRUGS IN THE YEAR 2000, supra note

86, at 78).
94. One could "bank" or "stoke" the fires biochemically so that activity could match
more closely the circumstances and thus allow man to devote more time to more exclusively human activities.
95. One is reminded of A Clockwork Orange, a film by Stanley Kubrik, from the book
by BURGESS, A CLOCKWORK ORANGE (1962).

96. Greater efficiency in education can be achieved by biochemically enhancing the
learning experience and thereby reducing the time required.
97. "How much simpler life would be if sufficient sepse of guilt could be produced
relevant to a particular type of situation to prevent its repetition. 'Punishment' would
then be truly rehabilitative and practically instantaneous." PSYCHOTRopic DRUGS INTIlE
YEAR 200, supra note 86, at 82.
98. Id. at 77.
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the scribbled scratch pad of an organic chemist."99 From the
drugs inception, two policy considerations will be in constant
conflict: safety versus the desire for swift development of new
substances. An institutional system has been set up with the hope
that as much as possible can be learned about a particular drug
before it is administered to humans; if, and when, it is ready for
human testing an attempt is made "to assure that clinical testing
of persons in hospitals, prisons, research facilities, or other institutions is carefully supervised."'' 0 The obvious goal of this system
is to minimize the risk that is inherent in the introduction of new
drugs. The other consideration is as important. Since "[t]here
is no such thing as absolute safety in drugs" 01 and since "certain
risks will have to be judged acceptable . . .[i]f major therapeutic breakthroughs are to be achieved .".,102, we are, "[a]t the
same time, . . . trying to speed up our actions so that drugs can

be marketed and made available to the physician and the patient
3
without unnecessary bureaucratic delays."10

This "tug of war" is present throughout the development of
all kinds of drugs. When, however, one is dealing with a psychopharmaceutical, there are intrinsic difficulties which render the
conflict more acute. For example, predicting drug effects across
specie lines in the first place has always been problematic:
"[d]uring the course of drug development, there are many instances where extrapolation of data from animals to man is difficult because the toxicologic and metabolic responses induced by
drugs may be significantly different between the laboratory species." 04 The trouble is enhanced significantly, however, when the
drug has potential therapeutic use in psychiatry, since all animals lack the mental faculties necessary to make such testing
effective. The development of the imipramine type of antidepressant is illustrative:' 5
Although they act as stimulants in the pigeon and in depressed
humans, anti-depressives of the imipramine type do not show
a classical "anti-depressive" pattern of activity in rodents, the
99. Drug Safety Hearings,supra note 19, pt. 2, at 518.
100. Finkel and Zatman, Investigationaland New Drugs, FDA Papers, Nov., 1970,
at 31.
101. Drug Safety Hearings, supra note 19, pt. 1, at 147.
102. Smith, Poutsiaka and Schreiber, Problems in Predicting Drug Effects Across
Species Lines, I J. INT. MED. RES. 489, 501 (1973).
103. Finkel and Zatman, supra note 100, at 31.
104. Smith, Poutsiaka and Schreiber, supra note 102, at 489.
105. Id. at 490.
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animals generally used to screen psychotropic agents. The fact
that the anti-depressive action of imipramine was discovered in
human beings. . . is, in itself, an interesting aspect of new-drug
development. If the original purpose of the tests in animals conducted on this class of drugs had been primarily to detect antidepressive activity per se, the compounds might never have
been evaluated in man, because they appeared to be weak
"tranquilizers" ....
B.

Human Testing

The difficulties do not cease once the decision is made to go
to human testing.' 6 With psychotropes, this is especially true
with regard to testing for efficacy,'"' which is required by the 1962
Kefauver-Harris Amendments"'8 to the Federal Food, Drug and
Cosmetic Act.' 9 The inherently subjective nature of
psychopharmaceuticals influences every stage of their development and use from pre-marketing testing to diagnosis and treatment. One doctor interviewed said, "There is no question that,
generally speaking, by the nature of the illness you're dealing
with, the testing of psychopharmaceuticals is more subjective;
the diagnosis of emotional disease requires a subjective element,
since you don't have something like a tumor in front of you."""
He quickly added that he was not describing a totally subjective
sittuation, for there are numerous physical and objective indicia
of the patient's reactions. He compared the testing of psychotropic drugs to the polygraph, in that both involve physical signs
of what is essentially a subjective determination, specifically,
truth and emotional states. Anxiety, then, can be defined in
terms of either a subjectively perceived state or of objectively
measured physiological parameters."'
For the most part, information regarding mental disorders is
derived from "some combination of the patient's and observer's
106. Section 505(i) of the Food and Drug Act, 21 U.S.C. §355(i) (1970), authorizes
the FDA to permit clinical investigations.
107. Of course, size of dose, rate of absortpion, rate of body distribution, rate of
elimination and degree of protein binding can greatly influence drug performance and
therefore it is necessary to have some detailed information of these factors prior to pursuing an investigation of drug efficacy.
4108. 76 Stat. 780 (1962).
109. 21 U.S.C. §§301-392 (1970).
110. Interview with Dr. Evan Morris, Assistant to Vice President-Medical Director,
Pfizer Pharmaceuticals, Inc., on December 7, 1973.
111. Interview with Dr. Kline on November 11, 1973. He noted that the problem of
subjectivity is not confined strictly to the field of psychiatry, naturally, the use of analgesics is analogous, since pain is not susceptible to objective measurement.
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subjective data. Validity of [this] approach has long been based
on 'common sense' and can rarely be verified. 1 12 [emphasis
added]. Usually, "rating scales" are used to quantify psychiatric
disease states,"' however, "[m]ood, esentially a private internal
experience, can be reported with accuracy only by a responsive,
cooperative subject. No rating scale is useful without a
respondent's cooperation." ' Even if the patient is sincere, authorities have noted that non-drug factors, such as sex, age and
intelligence, can affect the outcome of psychiatric drug therapy.'
One study attributed the variability of response to phenothiazines to differences in the personality structure of the drug recipient."' Marked differences in response were found between those
of the "extroverted athlete" class (low anxiety levels) and those
of the "introverted intellectual" class (high anxiety level).
C.

Diagnostic Variability

The World Health Organization has reaffirmed the existence
of great variability in psychiatric diagnosis in a recently published study of a major heuristic value." 7 The divergence has been
caused by a number of factors. Specifically, the report notes three
categories of influence."' The first involves the patients and
"their attitudes to and experience of mental illness and the person who attempted to treat it, their ideas about the nature of the
treatment, their social status, their desire for help, and the nature
and course of their illness.""' The characteristics of the clinician
are considered in the second category: that is their training, skills
and rules of classification. 120 Finally, the nature of the situation
is influential. This would include the circumstances (at home, in
hospital, in public, under constraint), the prevalent societal attitudes, the reaction of relatives and the relationship between doc2i
tor and patient.'
112. Cutler and Kurland, Clinical Quantificationof Depressive Reactions, 5 ARCH.
GEN. PSYCHIATRY 280 (1961).

113. Id.
114. Salzman et al., Rating Scales for Psychotropic Drug Research with Geriatric
Patients, I1, Mood Ratings, 20 J. AMER. GERIATRICS Soc. 215, 220 (1972).
115. Rickels, Some Comments on Non-Drug Factorsin PsychiatricDrug Therapy, 6
PSYCHOSOMATIS 303 (1965).
116. Heninger, Dimascio, and Klerman, Personality Factors in Variability of Response to Phenothiazines, 121 Am. J. PSYCH. 1091 (1964-65).
117. REPORT OF THE INTERNATIONAL PILOT STUDY OF SCHIZOPHRENIA, WORLD HEALTH
ORGANIZATION (1973).

118.
119.
120.
121.

Id., at 30.
Id.
Id.
Id.
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The report presented studies that are indicative of the degree
of diagnostic agreement among psychiatrists. One of these
showed that "there appeared to be good agreement on specific
organic disorders such as general paresis (90%), epileptic phychosis (92%) and mental retardation (91%), a lesser degree of
agreement on the functional psychoses (69%), and rather poor
agreement on the neuroses (24%). At worst, there was barely any
agreement at all.'1 2 It was mentioned that in the 1940's there was
123
similar disagreement among raters reading chest x-ray films.
An interesting question thus arises: are the discrepancies among
psychiatrists due to inherent subjectivity or is it rather a temporary phase in the state of the art, which is necessarily attendant
to the evolution of a new field of endeavor? If the latter be true,
it is a difficulty that is encountered in virtually every industry in
the field of products liability. 24 As the report suggests, 21 5
standardization of classification rules and other interviewing data
would minimize such inaccuracies. If the former hypothesis is
representative, we have a problem that time will not solve.
The differences in diagnostic results are clearest between
divergent cultural groups.
For example, a West Indian man who had recently arrived in
England, who belonged to a religious sect that practiced some
form of voodoo, and who had a poor command of English and
perhaps a low intelligence would be likely, if he became excited
or depressed, to present a clinical picture very different from
2
that represented by a well-educated Englishman. 1
Obviously, such a variance in diagnosis would not appear if both
the Englishman and the West Indian had infections. Bodily
structure and function remain remarkably similar despite cultural differences. The same cannot be said of mental illness. The
modus vivendi of a populace will produce its own signs or symptoms. We are not dealing with anatomy, but the way people live.
This example is, of course, paradigmatic, but it is indicative of
what occurs to a lesser extent within the same cultural group. One
122. Id., at 32.
123. Id.
124. E.g., Greenman v. Yuba Power Products, Inc., 59 Cal. 2d 57, 377 P.2d 897, 27
Cal. Rptr. 697 (1962), in which evidence was submitted tending to prove that there were
more positive ways of fastening the parts of the machine together.
125. REPoRT OF THE INTERNATIONAL PILOT STUDY OF SCHIZOPHRENIA, supra note 117, at
37.
126. Id., at 34.
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series of studies compared the diagnostic practices of England to
those prevalent in the United States: 2 '
The results of this exercise were fairly clear-cut. Hospital psychiatrists in New York did, as expected, diagnose schizophrenia
more frequently and affective disorders less frequently, than
hospital psychiatrists in London . . . . [these studies] indicate
that the prevailing concept of schizophrenia is much broader in
the United States than in Britain, embracing substantial parts
of what British psychiatrists would regard as depressive illness,
neurotic illness or personality disorder and almost the whole of
what they would regard as mania ....
The difficulties in diagnosis are theoretical as well as practical."' "In the first place, there is disagreement as to where to
draw the line between psychotic and non-psychotic conditions.
Indeed, there is even disagreement as to whether any line exists
at all.'
Some believe that there is an endogenous or psychotic
form of depression, while others maintain "that psychotic and
neurotic forms of depression lie on the same continuum (or continua), one shading imperceptibly into the other." 3 ' Complicating matters further is the fact that opinions with respect to therapy are often diametrically opposed; those doctors that abhor the
use of drugs may prefer convulsive treatment, while many find
the latter a barbaric practice.
Given all the conflicts, one encounters great difficulty in attempting to allocate responsibility. Ostensibly, the problem belongs to the medical profession, but recent trends in the products
field1 3' have indicated that the word "product" does not connote
a mere corporeal thing, i.e., the drug; it rather encompasses a
whole rational context. If this context encompasses more than the
independent decision maker, who is to undertake the Sisyphean
labor of reconciling the competing interests?

III.

THE

FDA

The efficacy of the FDA depends primarily on its ability to
127. Id., at 36.
128. Besides cultural differences, which have been discussed, the report specifies
several other "practical" considerations, namely, combinations of different forms of psychosis and previous clinical history influencing diagnosis of subsequent condition. Id., at
33.
129. Id., at 32.
130. Id., at 33.
131. E.g., Incollingo v. Ewing, 444 Pa. 263, 282 A.2d 206 (1971); Stevens v. Parke
Davis & Co., 9 Cal. 3d 51, 507 P.2d 653, 107 Cal. Rptr. 45 (1973).
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collect data and consequently this area of its activities has been
the source of much adverse comment. 3 2 One psychiatrist related
an incident wherein he called the FDA to inquire about the studies supporting a contraindication'3 3 that was listed for one of the
MAO inhibitors.'34 To his dismay, the FDA admitted after several
phone conversations that they had no data to support the directions. The FDA traced the decision to someone who had left the
agency, but it could not account for the evidence or reasoning
behind the contraindication.
Reporting of all side effects by the manufacturer is required
even where the causal relationship is tenuous.'35 Nevertheless,
3
some physicians'1
and manufacturers' 37 thwart the system by
withholding information on various grounds, usually inconclusivity. Indeed, the causation question is formidable in light of the
high incidence of polypharmacy (multi-drug therapy). 38
The problem of evaluating data obtained is more significant.
Any comprehensive drug surveillance program, in addition to ascertaining whether an untoward effect is related to a particular
durg, must be capable of estimating the type, magnitude and
frequency of its risk and benefit.'39 "[D]ata is presently provided
to the FDA in the form of spontaneous, voluntary reports . . .
[and these] . . . do not constitute an adequate method of sur132. E.g., Anello and Hanson, Drug Surveillancefor Adverse Reactions, FDA Papers,
March, 1971 at 6.
133. A contraindication is any symptom or circumstance indicating the inappropriateness of a form of treatment otherwise advisable.
134. The psychiatrist wishes to remain anonymous.
135. An FDA regulation, 21 C.F.R. §130.35(b)(7) (1973), requires the producer of a
new drug to disclose "any information concerning any side-effect, injury, toxicity, or
sensitivity reaction . . . which by kind, or incidence or severeity is not fully disclosed in
the labeling, whether or not determined to be attributable to the drug ... "
136. Merrill, supra note 58, at 6.
137. The flagrant withholding by Richardson-Merrell of data on MER/29 is familiar
history. See Rheingold, supra note 66; Toole v. Richardson-Merrell, Inc., 251 Cal. App.
689, 60 Cal. Rptr. 398 (Dist. Ct. App. 1967).
138. "[Ojne frequently finds the following conglomeration [of prescriptions for a
schizophrenic patienti: two phenothiazines (one high-dose and one low-dose); a tricyclic
antidepressant (the patient is withdrawn); an antiparkinson drug (even if the patient has
never shown any signs; this drug is completely superfluous in the presence of the anticholinergic tricyclic antidepressant); something for sleep; and something during the day to
keep the patient awake. Such a choice of drugs is no choice at all and has many irrational
aspects. Small wonder that some patients seem to improve after drugs are withdrawnl
• . ISItudies . . . fshow that no] . . . combination is superior for treating schizophrenics than a properly chosen single drug." Hollister, supra note 72, at 85.
139. Side effects associated with tricyclics include: dizziness, fatigue, constipation,
dryness of the mouth, gastrointestinal disturbances, liver damage, agitation, mania, tremors. paresthesias, memory impairment, seizures, headache, blurred vision, edema, body
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Side effects due to psychotropic agents vary
veillance .
"..."140
not only in degree, but in kind. This difference requires a qualitative analysis: should the dryness of the mouth that occurs persistently with the tricyclics be weighed equally with the occasional
impotence and delayed ejaculation that occurs with said drug?,
Consider also the fact that the decreased sexual sensitivity re42
turns to normal, "although this may take a number of months.
[emphasis added].
The problematic nature of the FDA decisional process is only
enhanced by the diversity of opinion within the psychiatric profession. The added difficulties are exemplified in the case of Parnate, an MAO inhibitor. Parnate was first marketed in February
1961. By February 1964 "approximately 400 cases of hypertensive
reaction, including 50 cerebrovascular accidents with 16 deaths,
had been reported.' ' 4 The FDA consulted eleven experts by
phone and they opined that the "therapeutic value of the drug
did not justify the number of serious adverse reactions which are
occurring."' 44 Consequently, approval of Parnate was withdrawn.
Letters from physicians and psychiatrists protesting the action
were received and a reevaluation of the drug ensued.
In June 1964 remarketing was permitted with a drastically
revised label. Several of the developments that influenced the
remarketing decision have been discussed elsewhere. 4 1 The usual
analytical problems were noted: a highly causal relationship between drug and reaction could only be established in about fifteen
percent of the reported cases; there was concomitant drug consumption in a high percentage of the cases. A survey of academic
psychiatrists showed thirteen favored marketing, four had no
comment and sixteen thought the drug was dispensable.' 46 A survey of twenty-one clinical investigators, however, unanimously
suggested that the drug, albeit potentially dangerous, "was rela'
This survey indicated
tively safe under proper precautions."147
weight hange, appetite change, skin sensitivity, hyperhidrosis (sweating), dysuria, sexual
disturbances and insomnia. The list is meaningless without a discussion of how often they
appear, to what extent and for how long. See KLINE, DEPRESSION: ITS DIAGNOSIS AND
TREATMFNT/LITHIUM: THE HISTORY OF ITS USE IN PSYCHIATRY 45-57 (3 MODERN PROBLEMS
OF PHARMACOPYSCHIATRY 1969).
140. Anello and Hanson, supra note 132, at 9.
141. KI.INE, supra note 139, at 49-55.
142. Id. at 55.
143. Drug Safety Hearings,supra note 19, pt. 3, at 1208.
144. Id.
145. Merrill, supra note 58, at 13.
146. Drug Safety Hearings,supra note 19, pt. 3, at 1210.
147. Id.
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that the more experience a physician had with Parnate, the more
favorably he viewed it. This evidence demonstrates the validity
of the suggestion that the drug should be confined to those who
use it frequently and can give the careful observational followup
that such a drug demands, i.e., the specialists.
The FDA has been criticized for its decision to remarket
Parnate.4 8 The reasons include failing to evaluate alternative
therapies, especially electro-convulsive treatment, and failure to
discover whether any patients were "Parnate specific", that is,
unresponsive to any other therapy. The presupposition inherent
in this criticism is that if a drug's beneficial properties are merely
cumulative vis-a-vis other available remedies, while its risk is
significantly higher, it should not be approved. In light of the
divergence of opinion among psychiatrists with respect to electroconvulsive and drug therapies, such a determination of substitutability is impossible.' Who can say authoritatively that Parnate
is superfluous in the presence of electroconvulsive treatment? Do
not those, both physician and patient, who abhor the use of the
latter method of treatment have a therapeutic right to have what
they consider a preferable therapy available to them? Assuming
the warnings are brutally honest, can we deny a person a drug
that may avoid severe depression and perhaps suicide- a possibility that always exists with the depressed patient? After the
decision to require drastic re-labeling, use of Parnate fell to thirty
percent of its former level.' 50 Perhaps this is the appropriate level:
if a drug has substantial therapeutic use, even if among a few,
and if the relevant data are honestly conveyed to the user,' such
a drug should be available to those who freely chose it. '
The author believes that the lesson to be derived from the
Parnate decision does not involve the specific points that were or
were not considered by the FDA, but rather the overall decisional
process. Dr. Joseph Sandusk was ultimately responsible for the
remarketing decision. He had become Director of the FDA's Bureau of Medicine on April 1, 1964,'11 during the period between
148. Id. at 1182 et seq.
149. See text accompanying note 130, supra.
150. Drug Safety Hearings, supra note 19, pt. 3, at 1213.
151. As to whether the user should be construed as the patient or physician for
purposes of information dissemination see section I.E, supra.
152. Note the possibility of promotional activities affecting choice, even on a subconscious level. See Stevens v. Parke, Davis & Co., 9 Cal. 3d 51, 507 P.2d 653, 107 Cal. Rptr.
45 (1973).
153. Drug Safety Hearings,supra note 19, pt. 3, at 1230.
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the initial decision to withdraw and the later decision to remarket. Was the decision to remarket merely the result of a change
of personnel, or of new insight?
These decisions . . . are made by the Medical Director based
on what he considers to be a consensus of opinion among his
staff. In other words, we do not hold a formal meeting in which
a vote pro and con is taken.'54
At the time of decision, only one psychiatrist was in the FDA's
Bureau of Medicine and he was opposed to recommending
reapproval of Parnate. 5 5 It is difficult to ascertain to what extent
the various factors contributed to Dr. Sadusk's decision. What
can be gleaned from Dr. Sadusk's testimony before the Senate
Subcommittee is that the ultimate decision was highly discretionary. It is the author's opinion that approval of psychotropic
substances is particularly susceptible to the hazards that traditionally inhere in discretionary judgment. Dr. Sandusk subsequently left the Bureau of Medicine5 to accept an executive position with Parke-Davis & Company. 1
Many are concerned that FDA pronouncements are not "institutional". 57 There are two considerations in making judgments
regarding drugs. The FDA which makes nationaldecisions must
consider all types of patients "with a multitude of disease processes",' 8 and doctors with varying degrees of skill. The average
practicing physician is "not necessarily qualified to make the
broader59 decisions about permitting nationwide marketing of a
drug."1
On the other hand, the safety and efficacy of a drug is not
an a priori determination. The drug's safety and efficacy is determined by its use and its use is a function of the attending physician. The physician can discuss the various side effects with the
patient; he can best discern the individual propensities of the
patient; he can aptly monitor the therapeutic response, and perhaps prevent a particular reaction by changing the dosage or, if
necessary, the drug. This individualized responsibility16 is borne
154. Id. at 1232.
155. Id. at 1233.
156. Merrill, supra note 58, at 13, n.47.
157. Drug Safety Hearings, supra note 19, pt. 3, at 1230.
158. Id., pt. 1, at 153.
159. Id.
160. The physician should do on a microcosmic scale what the FDA does, that is,
weigh benefit against risk, except he can personalize and modify the data to some extent
for he knows who the patient will be. The FDA can only consider the "collective" patient.
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by the physician and is only enhanced in the context of psychotropic drugs, which are inherently "individual."
The national decision precedes the individual one, however,
and
[the] agency has a responsibility to protect the American people, not the drug companies, not the doctors, but the American
people. The consuming public, the people who take these drugs,
may live or die, depending upon how safe and efficacious they
are."'
Some of those citizens concerned about having an institutional
and impartial data collecting and evaluating body have formed
a non-profit corporation called Medicine in the Public Interest
(MIPI). 112 Expressing "concern over the lack of concerted nonpublic, non-lobbying activity by the private sector in the health
'
care and scientific fields,"163
the organizers hope to develop a
"non-biased group or foundation"'' 4 whose function will be to
keep "policymakers and the public . . . better informed . .. "I"
The present board of directors is composed of four doctors,
but ultimately there will be nine or ten members, including members "from other disciplines, such as economics, law and sociology
... 1 By conducting "pharmacologic, medical, behavioral
and other scientific research and related legal research,"' 67 MIPI
will obtain analytical data which will be made " . . . available
for the benefit of the public, through educational presentations
and information dissemination via various media . . . ."I" If its
intentions are realized, MIPI may alleviate some of the problems
that exist in our current system, particularly, lack of both an
informed populace and an adequate regulatory procedure.
IV.

A.

COMPENSATING INJURIES

The Manufacturers

Since complete prohibition of the sale of a particular product
is a drastic decision in a free enterprise system, most "design"
defect cases focus on the adequacy of the product's warning. Drug
161. Drug Safety Hearings, supra note 19, pt. 3, at 1206.
162. MIPI was incorporated in Washington, D.C. on April 3, 1973 and is supported
principally by private contributions.
163. Statement of intent, called "The Need for Medicine in the Public Interest."
164. Id.
165. Id.
166. Id.
167. Articles of Incorporation of Medicine in the Public Interest, Inc.
168. Id.
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manufacturers who, in the past, have been hesitant, obfuscatory
or even deliberately evasive in their warnings' 6' are finding that
short range gains from such practices are outweighed by potential
liability. As mentioned earlier, 70 the psychopharmaceuticals are
apt to be overpromoted because of the somewhat nebulous nature
of the drugs' action and the lack of proficiency in their use among
general practitioners. By honest labeling and promotion, a drug
manufacturer can avoid liability and undoubtedly increase long
range profits.
For purposes of strict liability, many drugs have been termed
"unavoidably unsafe products" 7 ' and as a result the manufactures of such products have been afforded special consideration.
72
Commentj of section 402A of the Restatment (Second) of Torts'
defines an adequate warning as one that specifies side effects that
are foreseeable in a "substantial number" of users. The effect of
this qualification of that comment k113 is to render causes of action based on theories of negligence, breach of implied warranty
and strict liability "functionally interchangeable in most drug
injury cases."'7 In fact, ".

.

. there is not one case in a hundred

in which strict liability would result in recovery where negligence
would not.'

75

The duty, then, of a manufacturer to warn is fulfilled if he
keeps up with the relevant scientific findings, and conveys such
information to the physician."'7 Within the context of present law,
we might ask two questions regarding psychotropic drugs. First,
should the manufacturer be able to terminate his liability merely
by giving warning information to the physician, as has traditionally been the case?'77 This decision embraces a duty question
involving broad policy considerations: who do we want to know
what? The desirability of direct consumer warning has been discussed.' The second question one might ask concerns the obliga169. During the 1960's, several drug manufacturers underwent litigious examination
of their warnings. E.g., MER/29 (Richardson-Merrell), Aralen (Sterling Drug Co.) and
Chloromycetin (Parke-Davis); see Merrill, supra note 58, at 40-49.
170. See text accompanying note 73, supra.
171. RFSTATEMENT (SECOND) OF ToRTS §402A, Comment k, at 353-54 (1965).
172. Id., Comment j, at 353.
173. Id., Comment k, at 353-4.
174. Merrill, supra note 58, at 31.
175. Prosser, The Assault Upon the Citadel (Strict Liability to the Consumer), 69
YAi.F L.J. 1099, 1114 (1960).
176. Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969).
177. Carmen v. Eli Lilly & Co., 109 Ind. App. 76, 32 N.E.2d 729 (Ct. App. 1941).
178. See text accompanying notes 90-91, supra.
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tion of the drug manufacturers to initiate or enhance research so
as to be better able to identify the allergic user. Nowhere is such
research more important than in psychopharmacology, where the
good as well as detrimental effects of drugs are idiosyncratic.
Since adverse reactions have become an increasingly frequent problem 79 and since " . . .adverse reactions from psychotherapeutic drugs are far from completely known or explained,"18 it is imperative that manufacturers allocate resources
to research which will help physicians identify the allergic users,
whether or not their numbers are "substantial." Manufacturers,
for example, could be instrumental in standardizing some of the
diagnostic tools, such as rating charts, 8 ' and perhaps in further
defining the appropriate use of drugs in broad areas of
symptomalogy, such as the "depressed patient".'82 Although our
regulatory system has been criticized for placing inordinate financial demands on our drug industry,'83 there is contrary evidence.'
Therefore, it would seem manufacturers are probably able to sustain the increased financial burden that such an obligation would
impose. Even assuming that manufacturers' research has increased the foreseeability of injuries and that the results of their
research have been transmitted to the physician or patient, some
drug injuries will still be inevitable. "There is no such thing as
absolute safety in drugs.' 8 5
179. It has been estimated that the incidence of complications in drug therapy is 10
percent and that 5 percent of the patients admitted in general hospitals are receiving
treatment because of serious drug reactions. See Edwards, RationalDrug Therapeutics,
FDA Papers, Feb., 1971, at 4.
180. Hollister, PsychopharmacologicalDrugs, 196 J.A.M.A. 411, 412 (1966).
181. See text accompanying note 113, supra.
182. The problem of picking the correct drug for a specific kind or degree of depressed
patient is awesome, and primarily rests with the physician. The manufacturer, however,
could aid the practitioner by including in its labeling data on a wide range of patients.
At present, it is unlikely that manufacturers would have the incentive to restrict the use
of their product.
183. At an interview with Dr. Kline, supra note 52, he stated that "due to financial
considerations, the amount of new drugs being produced in the United States had been
radically reduced and it really is driving a substantial part of the industry out of the
United States." Also, Dr. Leslie Baer, during an interview on Dec. 12, 1973 stated that
he has used drugs for hypertension which are not so indicated. The reason that hypertension was not a primary indication is that the company did not want to incur the expense
necessary to have the FDA permit the additional indication. Dr. Norris of Pfizer Pharmaceuticals, Inc., supra note 110, stated, to the contrary, that manufacturers are most
anxious to test for as many indications as possible so as to enhance the prospective market.
184. The drug manufacturers spend $3,000 per year per physician on advertising; see
note 64, supra, and see text accompanying note 66, supra.
185. Drug Safety Hearings, supra note 19, pt. 1, at 147.
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If we have decided to explore mental and emotional illness
and its possible correction through drugs, should the isolated victims bear the cost themselves? As one commentator described the
realities of the situation,
Most reactions are the by-product of what amounts to government approved medical experimentation, conducted ostensibly
to advance society's interest in having available a broad range
of prescription medications.' 6
Such questions have been advanced under various theories that
can be conveniently labeled "risk distribution. 1 11 7 Calabresi has
18
been a prolific writer in this area.
Analysis of drug risk distribution has shown that there are
at least two different classes of drugs to consider.'89 If the drug is
taken in the treatment of a highly contagious disease (e.g.,
smallpox) the benefit derived from its success inures to society
as a whole, that is those who have been saved from contamination. But, if the patient suffers from an allergic reaction, the
classic "free rider" situation arises wherein the multitude receives the benefit of the treatment, whereas the individual bears
the injury alone. The second class of drugs appears to benefit the
user alone as the disease treated is not contagious (e.g.,
Parkinsonism). Theoretically, this risk should not be distributed
when society gains no benefit.
Whether one advocates risk distribution through taxation"'
or manufacturers' liability, it will be necessary to classify mental
and emotional afflictions. Mental illness is not considered to be
contagious and the primary benefit from drug consumption accrues to the patient. Yet, there is considerable benefit to be derived by society in having those, who would otherwise be incapacitated, leading functional and productive lives. Just the decrease
in hospital expenditures is significant."' Logically, then, the cost
of adverse reactions from psychotherapeutic drugs should be apportioned between user and society. The allocation would depend
186. Merrill, supra note 58, at 87-88.
187. Id., at 87-99.
188. See, e.g., G. CALABRESI, THE COST OF ACCIDENTS (1970); Calabresi, Does the Fault
S*ystem Optimally Control Primary Accident Costs?, 33 LAW & CONTEMP. PROB. 429
(1968); Calabresi, The Decision for Accidents: An Approach to Nonfault Allocations of
Costs, 78 HARV. L. REv. 713 (1965).
189. Merrill, supra note 58, at 99-102.
190. Id., at 103.
191. See Hollister, Clinical Use of PsychotherapeuticDrugs I: Antipsychotic and
Antimanic Drugs, 4 DRUGS 321, 323 (1972).
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on the degree of incapacitation (society gains more from the rehabilitation of a hospitalized psychotic patient than from the relief
of one's minor stress or depression).
Implementing a system of risk distribution, whereby the
manufacturer compensates the consumer for unforeseeable drug
injuries, would encourage the industry to spend more on the kind
of research mentioned above. 9 ' Under such a system, an unforeseeable reaction would render the manufacturer liable. But, if the
manufacturer helped bring the state of the art to the point where
the potential plaintiff could be identified before use, liability
would be avoided. In the latter case, the manufacturer's responsibility would cease and the physician might be liable for
prescribing after being adequately warned.
If courts are reluctant to accept a general risk distribution
theory, they might take a first step in that direction by redefining
the concept of implied warranty. Several attempts have been
made, although unsuccessfully. In Davis v. Wyeth Laboratories,
Inc. 9 the appellant contended the warranty should have been
construed to cover individuals rather than the public as a whole.
The latter interpretation would require only "that the vaccine
. . .have been reasonably fit and reasonably safe for use by the
public as a whole."'' A similar argument was proffered in Green
v. American Tobacco Co.' 95 Judge Cameron, dissenting, felt that
the implied warranty applied to the plaintiff, individually. Such
a theory would render every allergic reaction a breach of implied
warranty provided there was no misuse (e.g., not following dosage
directions).
Should the law develop, as suggested, to a point where all or
most adverse reactions are compensated by the manufacturer or
the physician, the only remaining hurdle would be proving causation. As the causes of mental and emotional illness are discovered
and as the mechanisms of psychotropic agents are revealed, proving causation will prove less formidable. As a consequence, numerous possibilities may unfold for legal action in psychopharmacology. Suppose a depressed patient visited a physician and an
appropriate psychotropic drug was prescribed. If the patient subsequently were to experience a severely increased depression,
there would be several possible explanations. The drug may have
192.
193.
194.
195.

See text accompanying notes 180-1, supra.
399 F.2d 121 (9th Cir. 1968).
Id. at 126 n.5.
304 F.2d 70 (5gh Cir. 1962).

http://scholarlycommons.law.hofstra.edu/hlr/vol2/iss2/18

28

Implications
Social
and
LegalThe
Dugan:
Legal
and Social
Implications of Psychopharmacology

been effective and minimized what might have been a more severe episode. The drug may have had no effect at all and the
disease syndrome continued as it would have without the medication. Finally, the drug may have caused the depressive progression. In the second illustration, the manufacturer might incur
liability and in the third he definitely would.
Such a hypothetical involves weighty causation problems
and courts anticipating them would probably find that the defendant owed the plaintiff no duty. For example, courts have hesitated to find a duty on the part of the defendants to minimize the
risk of second collision injuries.'90 As better evidence on second
collision causation became available,'97 some courts began to
establish this duty. 98 We may see the same process in psychopharmacology. The irony is that now when psychopharmacology
is in its infancy and the dangers are numerous, such a cause of
action would be overly speculative. As the state of the art in
psychiatry improves, the dangers will lessen, but the increased
insight will afford an appropriate basis for a products liability
suit.
B. The PrescribingPhysician
If liability follows responsibility, the physician may emerge
as the primary target in future drug injury cases. If the FDA's
requirements are satisfied and if the manufacturer reports all it
knows to the physician, the buck stops there. "The next deep
pocket behind that of the manufacturer is the physician's," 99and
there are several new and developing ways to get to it.
The package insert, for instance, has dual implications. As
it affords the manufacturer more and more protection from liability, the same instrument is rendering the practitioner more vulnerable to a malpractice suit. Although the FDA regulates its
contents, to some extent, the package insert "is, in essence, a
promotional item. ' ' 20 ' The FDA decides what drugs are on the

market, not how they are to be used and thus, has no jurisdiction
196. E.g., Evans v. General Motors Corp., 359 F.2d 822 (7th Cir.), cert. denied, 385
U.S. 836 (1966).
197. E.g., "It is a matter of common knowledge that state and federal authorities,
non-governmental agencies, and legal and medical groups, as well as automotive producers, are currently engaged in research, discussion and hearings .... Evans v. General
Motors Corp., 359 F.2d 822 (7th Cir. 1966) (Kiley, J., dissenting).
198. E.g., Larsen v. General Motors Corp., 391 F.2d 495 (8th Cir. 1968).
199. Tozer and Kasik, The Medical-Legal Aspects of Adverse Drug Reactions, 8
CLUN. PHARM. THER. 637, 639 (1967).
200. Editorial, 207 J.A.M.A. 1342 (1969).
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to compel adherence to the brochure's directives. "A wellinformed physician . . .possesses greater knowledge both in

depth and in breadth than that outlined in a package insert." ''
Yet, deviation is often difficult to defend. Recent trends indicate
that "an erosion of the community standard rules in malpractice
The
litigation involving prescription drugs"2"2 is taking place.
3
that:1
said
has
example,
for
Court,
Minnesota Supreme
[A] doctor's deviation from such recommendation [in the
package insert] is prima facie evidence of negligence if there is
competent medical testimony that his patient's injury or death
resulted from the doctor's failure to adhere to to the recommendations.
In another case involving Promazine, a phenothiazine derivative
(major tranquilizer), the package circular stated that eighteen
instances of agranulocytosis had occurred among three and a half
million patients and further provided directions for observational
followup. The court said that the package insert would absolve
"the manufacturer from any liability in warranty."' "4 The record
did, however, warrant an inference of negligence on the part of
the prescribing physician "who failed to follow directions emanating from the manufacturer . .2.0."5 The package insert, in

the area of psychopharmacology, may have a desirable disciplinary effect on general practitioners, but may just as easily inhibit
sound medical judgment among psychiatrists. Dr. Kline, who has
actively practiced psychiatry for twenty-five years, stated that
one cannot properly have anything that approximates "absolute"
directions in psychopharmacology.2 0 As Dr. Kline said, "It would
be like saying the proper manner in which to approach a tort case
is this and only this one because we have statistical proof that
sixty percent of the cases are won that way.

' 20 7

Physicians are also subject to an increasing number of malpractice suits on the basis of lack of "informed consent". This is
occurring in cases that involve nonsurgical aspects of medical
201. Id.
202. Merrill, supra note 58, at 62.
203. Mulder v. Parke Davis & Co., 288 Minn. 332,339-40, 181 N.W.2d 882, 887 (1970).

204. Magee v. Wyeth Laboratories, Inc., 214 Cal. App. 2d 168,
322, 328
205.
206.
207.

,

29 Cal. Rptr.

(Dist. Ct. App. 1963).
, 29 Cal. Rptr. at 327.
Id., at
Interview with Dr. Kline, supra note 52.
Id.
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care, such as insulin shock therapy,0 8 treatment with radioactive
cobalt0 following a mastectomy, 29 or the use of a spinal anesthetic.

21

Insulin-shock therapy is used to treat a psychiatric patient
who is unresponsive to other therapies. In a Missouri case, involving fractures resulting from convulsions induced by insulin therapy, the court said that ".

.

. the doctors owed their patient in

possession of his faculties the duty to inform him generally of the
*...
,, The same court qualpossible serious collateral hazards .
ified this holding in a subsequent insulin therapy case by saying
that the question of what disclosure of risks should be made in a
given situation is a medical judgment determined by the normal
practices of the reasonable practitioner in the particular community.212 Both these cases involved a drug-related injury and the
issue was how extensive the warning must be in order for the
consent obtained to qualify as an informed consent. The law of
the immediate future will most likely specify to what degree the
manufacturer's warnings must be passed on to the user. A physician prescribing psychopharmaceuticals will, however, face
unique considerations in making this choice.
It is, of course, not desirable to have disclosure of possible
risks where such disclosure "may have such an adverse effect on
the patient as to jeopardize success of the proposed
",213 Conveying to an extremely anxious patient the
therapy ....
reactions could understandably diminish the efadverse
possible
ficacy of an antianxiety agent. The extent of disclosure, then, is
a matter of professional discretion, but patients will have to be
let in on some of "the mysteries of drug use" which have heretofore been "solely the province of the physicians and drug companies. ' ' 21 4 The information need not be detailed nor confusing, for

as the Missouri court said, "[Tihe duty [is] to inform him
generally of the possible . . . hazards .... 11215 [emphasis
added]. Special importance should be attached to informing the
patient of possible behavioral reactions to psychotropic drugs. A
208. Mitchell v. Robinson, 334 S.W.2d 11 (Mo. 1960); Aiken v. Clary, 396 S.W.2d 668
(Mo. 1965).
209. Natanson v. Kline, 186 Kan. 393, 350 P.2d 1093 (1960).
210. Mayor v. Dowsett, 400 P.2d 234 (Ore. 1965).
211. Mitchell v. Robinson, 334 S.W.2d 11, 19 (Mo. 1960).
212. Aiken v. Clary, 396 S.W.2d 668 (Mo. 1965).
213. Id. at 674.
214. Turner, supra note 59, at 301.
215. Mitchell v. Robinson, 334 S.W.2d 11, 19 (Mo. 1960).
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patient may prefer a restlessness engendering drug to one that
impairs sexual capacity and for this reason, "[the] importance
of various side effects to the patient should be a guide in choosing
his specific treatment. 21 This is all part of the more individualized concept of benefit versus risk, called the "art of psychopharmacology", 217 and responsibility for an accurate balancing of interests rests primarily with the physician.
CONCLUSION

Statistics show that psychopharmaceutical consumption
trends in the United States are not atypical of Western industrialized nations. 2 8 The United States can, however, be a forerunner in devising and implementing effective policies in this field.
We must ask ourselves if it is prudent to proceed the same way
with a drug that affects our minds as we do with one that can
harm us physically. We must also consider that we are dealing
with a new generic class of drugs such that the undesirable effects
may not emerge for several generations.
More fundamental than a need for more knowledge is the
necessity of deciding how to use what we already know. "In a
sense, we are in the same ethical and moral dilemma as the
physicists in the days prior to the Manhattan Project.1 21 1 One
psychiatrist said that if there is a Mount Everest there, we will
climb it. The issue, however, is not the ascent, but determining
which route will be the safest.
Thomas P. Dugan
216. Hollister, supra note 72, at 84.
217. Shader, supra note 39, at 83.
218. Parry et al., supra note 3, at 769.
219. Evans, Introduction to PSYCHOTROPIc DRUGS IN THE YEAR 2000, supra note 86, at
XX.
220. Interview with Dr. Kline, supra note 52.
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APPENDIX I
Table L-Classification of Psychotherapeutic Drugs
Examples: Generic Names

Examples: Tradenames

Prescription (Rx)
Major Tranquillizers
Phenothiazine derivatives Chlorpromazine, thioridazine

Thorazine, Mellarll

Butyiophenones

Haloperidol

Haldol

Thioxanthenes

Thiothixene, chlorprothixene

Navane, Taractan

Major Tranquilizers
Substituted diols

Meprobamate, tybamate

Equanil, Miltown, Tybatran

Benzodrazepines

Chlordiazepoxide, diazepam,
oxazepam

Librium, Valium, Serax

Miscellaneous

Hydroxyzine, buclizine

Atarax, Softran

Antidepressants
Tricyclics

Imipramine, amitriptyline

Tofranil, Elavil

MAO inhibitors

Isocarboxazid, phenelzine

Marplan, Nardil

Other

Methylphenidate, combination
of amitriptyline &
perphenazine

Ritalin, Triavil, Etrafon

Dextroamphetamine (& combinations), methamphetamine

Dexedrine, Dexamyl, Desoxyn

Deanol, pentylenetetrazol
(& combinations)

Deaner, Metrazol

Phenobarbital, butabarbital

Eskabarb, Butisol

Bromisovalum

Bromural

Stimulants
Amphetamines
Others
Sedatives
Barbituates (long-acting
& intermediate-acting)
Others

Hypnotics
Barbiturates (short-acting) Secobarbital, pentobarbital
Others
Glutethimide, ethchlorvynol

Seconal, Nembutal
Doriden, Placidyl

Over the Counter
Stimulants

Caffeine

No-doz, Vivarin, No-nod

Tranquilizers

Scopolamine and/or
methapyrilene

Cope, Compoz

Sleeping pills

Scopolamine and/or
methapyrilene

Sleep-Eze, Mr. Sleep,
Sominex, Nytol

Source-Parry, et al., National Patterns of
GEN. PSYCHATRY 769, 772 (1973).
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APPENDIX II
PROBABLE FUTURE ALTERATIONS OF LIFE PATERNS BY DRUGS
1.
2.
3.
4.
5.
6.
7.
8.
9.

10.
11.
12.
13.
14.
15.

Prolong Childhood and (Shorten?) Adolescence
Reduce Need for Sleep
Provide Safe, Short-acting Intoxicants
Regulate Sexual Responses
Control Affect and Aggression
Mediate Nutrition, Metabolism and Physical Growth
Increase or Decrease Reactivity (Alertness, Relaxation)
Prolong or Shorten Memory
Induce or Prevent Learning
a. Experience without reinforcement
b. Vicariously with reinforcement
Produce or Discontinue Transference
Provoke or Relieve Guilt
Foster or Terminate Mothering Behavior
Shorten or Extend Experienced Time
Create Conditions of i'amais vu (Novelty) or deja vu (Familiarity)
Deepen our Awareness of Beauty and our Sense of Awe

Source-PsYcHoTRopic DRUGS IN THE YEAR 2000, at 78 (W. Evans and N. Kline, eds.,
1971).
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